Angiogenic Blockade and Radiotherapy in Hepatocellular Carcinoma

Chi, Kwan‐Hwa; Liao, Chao‐Sheng; Chang, Chia Ju; Ko, Hui-Ling; Tsang, Yuk-Wah; Yang, Kuo-Ching; Mehta, Minesh P.

doi:10.1016/j.ijrobp.2009.07.1725

Cited by 47 publications

(26 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…34,35 Thus, such high-risk patients may benefit from concomitant systemic therapy such as novel agents to block multimolecular pathways. [35][36][37] This study has several limitations. First, quantitative assessments of changes in maximal tumor SUV from baseline after completion of chemoradiotherapy were not performed.…”

Section: Discussionmentioning

confidence: 99%

¹⁸F‐fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma

Kim

Kang

Kim

et al. 2011

Cancer

View full text Add to dashboard Cite

BACKGROUND: Metabolic activity assessed by 18 F-fluorodeoxyglocuse-positron emission tomography ( 18 F-FDG-PET) reflects biological aggressiveness and prognoses in various tumors. The authors present a correlation between tumor metabolic activity and clinical outcomes in patients with hepatocellular carcinoma (HCC). METHODS: Over a 3-year period (2005)(2006)(2007)(2008), 135 locally advanced HCC patients were treated with localized concurrent chemoradiotherapy (CCRT; external beam radiotherapy at 45 grays for 5 weeks plus concurrent hepatic arterial infusion of 5-fluorouracil during the first and fifth week) followed by repetitive hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin. Among them, the authors studied 107 who received 18 F-FDG-PET before CCRT. Maximal standardized uptake values (SUVs) of tumors were calculated. RESULTS: The median maximal tumor SUV was 6.1 (range, 2.4-$19.2). Patients with low maximal tumor SUVs (<6.1) had a higher disease control rate than those with high maximal tumor SUVs (!6.1) (86.8% vs 68.5%, respectively, P ¼ .023). Both median progression-free survival (PFS; 8.4 vs 5.2 months; P ¼ .003) and overall survival (OS; 17.9 vs 11.3 months; P ¼ .013) were significantly longer in the low maximal tumor SUV group than in the high maximal tumor SUV group, respectively. In multivariate analysis, low maximal tumor SUV and objective responses to CCRT remained significant for PFS and OS. The high maximal tumor SUV group was more likely to have extrahepatic metastasis within 6 months than the low maximal tumor SUV group (58.1% vs 26.8%, respectively; P < .001). Similar results were obtained for the maximal tumor SUV/normal liver maximal SUV ratio (<2 vs !2) concerning progression, death, and extrahepatic metastasis. CONCLUSIONS: Metabolic activity may be useful not only in predicting prognosis and treatment responses, but also in establishing optimal treatment plans in locally advanced HCC. Cancer 2011;117:4779-

show abstract

Section: Discussionmentioning

confidence: 99%

¹⁸F‐fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma

Kim

Kang

Kim

et al. 2011

Cancer

View full text Add to dashboard Cite

show abstract

“…Theoretically, rapid eradication of macro-targets by radiotherapy would decrease the chance of drug resistance during effective systemic treatment. Multi-target radiotherapy using a relatively new technology as helical tomotherapy has been shown to be effective and convenient with acceptable toxicities [10][11][12]. Tomotherapy has little limitations in target numbers and field size restriction.…”

Section: Introductionmentioning

confidence: 99%

Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: A mono-institutional experience

Chang¹,

Chi²,

Kao³

et al. 2011

Lung Cancer

Self Cite

View full text Add to dashboard Cite

“…Targeted agents that have been tested with radiotherapy include sunitinib and sorafenib. Thus far, combining those agents with radiotherapy has led to increased toxicity, especially gastrointestinal toxicity, which in some cases has been fatal [52][53][54] . Concurrent use of those systemic agents with radiotherapy off-study is therefore not currently recommended.…”

Section: Summary Of Evidencementioning

confidence: 99%

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016

Bossé

Ahmad

et al. 2016

Current Oncology

View full text Add to dashboard Cite

The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016 was held in Montreal, Quebec, 5-7 February. Experts in radiation oncology, medical oncology, surgical oncology, and infectious diseases involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics:■ Follow-up and survivorship of patients with resected colorectal cancer ■ Indications for liver metastasectomy ■ Treatment of oligometastases by stereotactic body radiation therapy ■ Treatment of borderline resectable and unresectable pancreatic cancer ■ Transarterial chemoembolization in hepatocellular carcinoma ■ Infectious complications of antineoplastic agents

show abstract

Angiogenic Blockade and Radiotherapy in Hepatocellular Carcinoma

Cited by 47 publications

References 32 publications

¹⁸F‐fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma

¹⁸F‐fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma

Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: A mono-institutional experience

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016

Contact Info

Product

Resources

About

Angiogenic Blockade and Radiotherapy in Hepatocellular Carcinoma

Cited by 47 publications

References 32 publications

18F‐fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma

18F‐fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma

Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: A mono-institutional experience

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016

Contact Info

Product

Resources

About

¹⁸F‐fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma

¹⁸F‐fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma